Cassava Sciences' stock rose 9% after completing an interim safety analysis for its Alzheimer's drug, Simufilam, but the company's future remains uncertain due to ongoing legal and scientific scrutiny ...

Investors with a lot of money to spend have taken a bearish stance on Cassava Sciences (NASDAQ:SAVA). And retail traders should know. We noticed this today when the trades showed up on publicly ...

Shares of biotech company Cassava Sciences Inc. plummeted on Friday after a federal grand jury indicted a onetime science advisor to Cassava and charged him with falsifying data to obtain millions of ...

An independent DSMB reviewed interim safety data for simufilam and recommended the trials proceed without modifications. Two ongoing trials with over 1,900 Alzheimer’s patients; top-line results from ...

News is the latest setback for the clinical-stage biotech, which was the subject of SEC and Justice Department investigations earlier this year Cassava Sciences Inc.'s stock tumbled 85% Monday to put ...

Cassava Sciences' pivot to TSC via a Yale license deal for simufilam addresses both new indications and reputation issues but faces significant clinical and market challenges. Preclinical studies show ...

Cassava Sciences' shares fell sharply Tuesday morning after the company said it would discontinue the development of its Alzheimer's treatment after recent trials didn't meet any of their objectives.